Skip to search formSkip to main contentSkip to account menu

DAB(486)-interleukin 2

Known as: DAB(486)-IL-2, DAB486-IL-2, interleukin 2 toxin 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (5)

Antineoplastic AgentsAntirheumatic AgentsDiphtheria ToxinInterleukin-2

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1995
Review
1995
Diphtheria toxin-based receptor-specific chimaeric toxins as targeted therapies.
The results from the phase I/II studies of the intravenous administration of DAB486-IL-2 to patients with refractory… 
1992
1992
Interleukin 2 receptor targeted fusion toxin (DAB486‐IL‐2) treatment blocks diabetogenic autoimmunity in non‐obese diabetic mice
Insulin‐dependent diabetes mellitus (IDDM) is strikingly similar in the non‐obese diabetic (NOD) mouse and humans. In IDDM, the… 
1992
1992
Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Review
1992
Review
1992
Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
1991
1991
Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells.
We have used site-directed insertion and point mutagenesis in an attempt to increase the cytotoxic potency and receptor-binding… 
1990
1990
Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.
During the proliferative burst after Ag recognition, T cells express cell-surface, high-affinity IL-2R. The importance of IL-2R… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)